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Abstract
Apoptosis contributes to cell death in common intensive care unit
disorders such as traumatic brain injury and sepsis. Recent
evidence suggests that this form of cell death is both clinically
relevant and a potential therapeutic target in critical illness. Mito-
chondrial reactive oxygen species (ROS) have become a target for
drug discovery in recent years since their production is charac-
teristic of early stages of apoptosis. Among many antioxidant agents,
stable nitroxide radicals targeted to mitochondria have attracted
attention due to their ability to combine electron and free radical
scavenging action with recycling capacities. Specific mechanisms
of enhanced ROS generation in mitochondria and their translation
into apoptotic signals are not well understood. This review focuses
on several contemporary aspects of oxidative stress-mediated
mitochondrial injury, particularly as they relate to oxidation of lipids
and their specific signaling roles in apoptosis and phagocytosis of
apoptotic cells.
The recent realization that mitochondria are at the inter-
section of the life and death of a cell, particularly through the
involvement of mitochondrial damage in a range of diseases,
has made them a promising target for drug discovery and
therapeutic interventions [1]. Several types of critical
illnesses are associated with cell death, both necrotic and
apoptotic. The significant contributions of apoptotic pathways
in cell death and to the pathogenesis of common intensive
care unit (ICU) disorders, such as traumatic brain injury, acute
respiratory distress syndrome, and sepsis, are well
appreciated [2-4]. Because apoptosis usually includes
mitochondrial injury, production of reactive oxygen species
(ROS) and oxidative stress, this review is focused on
apoptotic mechanisms through which oxidative stress realizes
its signaling functions. This review is not a comprehensive
analysis of available literature on this subject but rather is
focused on several contemporary aspects of oxidative stress-
mediated mitochondrial injury, particularly as they relate to
oxidation of lipids and their specific signaling roles in
apoptosis.
Apoptosis
Apoptosis, or programmed cell death, is a series of well
coordinated and strictly controlled processes in which ligand
binding to specific (death) receptors or cytotoxic insults
result in the activation of several proteases and other
hydrolytic enzymes, leading to proteolysis, DNA fragmen-
tation and chromatin condensation [5]. Programmed cell
death can be executed via extrinsic and intrinsic pathways
depending on the stimulus leading to apoptosis (Figure 1).
Extrinsic signals (such as cytokines, tumor necrosis factor
(TNF)-α, Fas ligand, glucocorticoids) bind to their receptors
and trigger intracellular signaling leading to caspase-8
activation [6]. The TNF and Fas ligand pathways can induce
both apoptosis and cell survival depending on the
intracellular signaling pathways that are induced by them, and
the balance seems to be related to activation of nuclear
factor-κB [6].
In the intrinsic apoptotic pathway, pro-apoptotic signals (such
as the pro-papototic Bcl-2 family proteins Bax and Bak)
translocate to mitochondria, resulting in mitochondrial mem-
brane permeabilization. This in turn provides a route for
release of intermembrane space proteins (such as cyto-
chrome c, apoptosis inducing factor (AIF), Endo G and
Smac/DIABLO (Second mitochondria-derived activator of
caspase/direct IAP binding protein with a low pI)) into the
cytosol. Once in the cytosol, cytochrome c promotes the
formation of the ‘apoptosome’, a molecular platform for the
activation of caspase-9. The apoptosome also includes the
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apoptosis protease activating factor 1 (APAF-1) and ATP/
dATP. In turn, active caspase-9 catalyzes the proteolytic
activation of the effector caspases. This leads to the expres-
sion of two key apoptotic phenotypes, namely, exposure of
phosphatidylserine (PS) on the outer surface of plasma
membrane and DNA fragmentation and degradation. Recent
studies show that caspase 3 may also serve to amplify the
initial death signal by helping to promote further cytochrome
c release from mitochondria [7]. Smac/DIABLO promote
apoptosis indirectly, by binding to and antagonizing members
of the inhibitor of apoptosis protein (IAP) family. AIF and Endo
G, on the other hand, translocate from the cytosol to the
nuclear compartment, leading to DNA fragmentation and
chromatin condensation [5,8].
Figure 1
Programmed cell death can be executed via extrinsic and intrinsic pathways depending on the stimulus leading to apoptosis. In the intrinsic
apoptotic pathway, pro-apoptotic signals (such as pro-apoptotic Bcl-2 family proteins Bax and Bak) translocate to mitochondria, resulting in
mitochondrial membrane permeabilization. This in turn provides a route for release of intermembrane space proteins (such as cytochrome c (Cyt c),
apoptosis inducing factor (AIF), Endo G and Smac/DIABLO (Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis
protein binding protein with a low pI)) into the cytosol. Once in the cytosol, cytochrome c promotes the formation of the ‘apoptosome’, a molecular
platform for the activation of caspase-9. In turn, active caspase-9 catalyzes the proteolytic activation of caspase-3. This leads to DNA fragmentation
and chromatin condensation. Caspase 3 may also serve to amplify the initial death signal by helping to promote further cytochrome c release from
mitochondria. Smac/DIABLO and Omi stress-regulated endoprotease/high temperature requirement protein A2 (Omi/HtrA2) promote apoptosis
indirectly by binding to and antagonizing members of the inhibitor of apoptosis protein (IAP) family. AIF and Endo G, on the other hand, translocate
from the cytosol to the nuclear compartment, leading to DNA fragmentation and chromatin condensation. Extrinsic signals bind to their receptors
and trigger intracellular signaling, leading to caspase-8 activation. Activation of caspase-8 by extrinsic stimuli (such as tumor necrosis factor-α, Fas
ligand) involves mitochondria-dependent signaling (in type II cells) and results in cleavage of the pro-apoptotic Bcl-2 family protein Bid to t-Bid.
Translocation of t-Bid to the mitochondria is believed to be one of the signals for mitochondrial events during apoptosis. In type I cells, on the other
hand, execution of apoptosis occurs without significant participation of mitochondria. APAF-1, apoptosis protease activating factor 1; ER,
endoplasmic reticulum.Page 3 of 11
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The mechanisms by which the intermembrane space proteins
are released from mitochondria remain controversial [9]. In
general, two mechanisms have been described, the occurrence
of either of which might depend on the nature of the apoptotic
stimulus. In the first mechanism, a permeability transition pore
opens in the inner membrane, allowing water and molecules up
to 1.5 kDa to pass through [10]. Although alternative models
have been proposed [11], most models imply that the adenine
nucleotide transporter in the inner membrane and the voltage
dependent anion channel in the outer membrane are
components of this pore [12]. Opening of the permeability
transition pore leads to equilibration of ions across the inner
mitochondrial membrane with loss of mitochondrial
transmembrane potential (Δψ) and swelling of the matrix as
water enters. The latter can result in sufficient swelling to break
the outer membrane, resulting in the release of pro-apoptotic
factors from the intermembrane space to the cytosol.
The second mechanism is mediated by Bcl-2 family members
acting directly on the outer mitochondrial membrane. In this
process, oligomerization of pro-apoptotic Bcl-2 family members
Bax and Bak plays an essential role in the permeabilization of
the outer mitochondrial membrane [13]. We and others have
shown that Bax/Bak translocation to mitochondria causes ROS
generation and cardiolipin (CL) oxidation in the mitochondria
[14-15]. In Bax/Bak double knock out cells, ROS production
and CL oxidation are decreased. These cells, but not cells
lacking only one of these proteins, have been found to be
resistant to a variety of apoptotic stimuli, including oxidants,
that act through the mitochondrial pathway [16]. Irrespective of
its mechanisms, permeabilization of the mitochondrial outer
membrane is considered a point of no return for programmed
cell death because of the release of caspase activators such as
cytochrome c.
Mitochondria appear to be involved in both the extrinsic and
intrinsic apoptotic pathways. While the intrinsic apoptotic
pathway is mitochondria dependent, cells undergoing
programmed death via the extrinsic pathway can be classified
as type I and II depending on whether the mitochondria is
involved or not. In type I cells, execution of apoptosis occurs
without significant participation of mitochondria. This kind of
cell death mechanism may be important for developmental
tissue remodeling [18]. In type II cells on the other hand,
mitochondria are involved in the execution of apoptosis as a
second loop. In some membrane death receptor-mediated
systems, activation of caspase-8 by extrinsic stimuli (such as
TNF-α and Fas ligand) involves mitochondria-dependent
signaling and results in cleavage of the pro-apototic Bcl-2
family protein Bid to t-Bid. Translocation of t-Bid to
mitochondria is believed to be one of the signals triggering
mitochondrial events during apoptosis [5].
Mitochondrial energy production
Mitochondria play a critical role in cellular energy production
via electron transport chain-dependent synthesis of ATP.
Derangements in mitochondrial function mostly affect cells
that have a high energy demand, such as neurons and
cardiac myocytes. The mitochondrial electron transport chain
is composed of five multimeric complexes [19]. Electron
transport between complexes I to IV is coupled to extrusion of
protons from complexes I, III and IV into intermembrane
space, creating an electrochemical gradient (Δψ) across the
inner mitochondrial membrane (Figure 2). This movement of
electrons generates an alkaline matrix and an acidic
intermembrane space. Protons then flow through complex V
(ATP synthase), which utilizes the energy to synthesize ATP
from ADP [20].
Since molecular oxygen is the terminal electron acceptor in
the mitochondrial electron transport chain, assessments of
mitochondrial function are often performed through the
measurement of oxygen consumption in isolated mito-
chondria. Intact mitochondria provided with inorganic
phosphate and an oxidizable substrate (such as succinate)
respire relatively slowly in the absence of ADP. Addition of
ADP initiates a sudden burst of vigorous respiration and the
ADP is rapidly phosphorylated to produce ATP. This is called
coupled respiration: oxygen consumption is coupled to the
production of ATP. When all the ADP is depleted, the
respiration rate returns to its original level. The active rate in
the presence of ADP is called ‘state 3 respiration’ and the
slower rate when all the ADP has been phosphorylated is
referred to as ‘state 4 respiration’. State 4 respiration reflects
the rate of leakage of proton back across the inner
mitochondrial membrane into the matrix and is not coupled to
complex V or ATP synthesis. The ratio of state 3 to state 4 is
called the respiratory control index. This ratio varies with the
substrate and the experimental details; in general, it is at least
5 or greater if the isolated mitochondria are in good
condition. In state 3 respiration, control of respiration may
involve several components, including the adenine nucleotide
translocator and cytochrome c oxidase [20-24]. The extra-
mitochondrial ATP/ADP ratio, extramitochondrial Pi concen-
tration and the supply of hydrogen also play significant roles
in controlling respiration [25]. Under disease conditions
decreased state 3 respiration and increased state 4
respiration may be observed. Many compounds can inhibit
mitochondrial respiration; the precise pattern of inhibition
differs from one compound to the next. Important inhibitors
are cyanide, antimycin, rotenone and oligomycin, all of which
block different components of the electron transport chain
(Figure 2). A small group of compounds called uncoupling
agents cause unrestrained oxygen uptake in the absence of
ADP. None of the energy released during this type of
oxidation is captured; it is all dissipated as heat [26].
An important component of the electron transport chain,
cytochrome c is located in the intermembrane space and
shuttles electrons between mitochondrial complexes III and
IV. In addition to this well known and essential function,
cytochrome c plays a critical role in the activation of
Available online http://ccforum.com/content/12/1/206caspases during apoptosis [27]. Release of cytochrome c
from mitochondria is one of the early stages of the apoptotic
program, designating a point of no return in a cell’s
disintegration. It is also believed that the detachment of
cytochrome c from the inner membrane and its release into
the cytosol is one of the rate limiting events in the execution
of the apoptotic program [28].
Mitochondrial dysfunction in critical illness
Mitochondrial dysfunction has been reported during critical
illness in the ICU. We will briefly mention studies on sepsis
and severe traumatic brain injury. The reader is referred to
excellent reviews specifically describing mitochondrial
dysfunction in these disease states [29-31]. Long term
laboratory models of sepsis (>12 hours) and sparse human
data have shown decreases in mitochondrial activity or ATP
concentrations [32-34]. In septic shock patients examined
within 24 hours of ICU admission, the degree of skeletal
muscle mitochondrial dysfunction was associated with the
severity of the disease [32]. In this work, tissue ATP levels
were significantly lower in non-survivors than in an orthopedic
surgical control population, but they were maintained in those
who survived sepsis. Complex I activity had a significant
inverse correlation with norepinephrine requirements and
nitrite/nitrate concentrations. The pathogenesis of mito-
chondrial dysfunction during sepsis is complex and multi-
factorial. Nitric oxide (NO), with its inhibitory effects on
electron transport chain complexes, is believed to play an
important role [29]. However, it has also been shown that low
levels of NO stimulate mitochondrial proliferation, suggesting
that effects of NO on mitochondrial function during sepsis
depend on its concentration and the timing of its release [35].
An alternative idea suggested by some investigators is that
mitochondrial dysfunction during sepsis may be due to an
adaptive cellular strategy to reduce cellular energy
expenditure, similar to hibernation [29].
Studies in traumatic brain injury also suggest derangements
in mitochondrial function in experimental models and humans
[30]. Mitochondrial dysfunction has been documented after
both experimental and clinical head injury [30,36-39]. Studies
in rodents suggest that alterations in mitochondrial function
begin early and may persist for days following injury. A recent
work evaluated the time course of cortical mitochondrial
dysfunction in adult mice after experimental traumatic brain
injury [40]. The results showed impairment in mitochondrial
bioenergetics concomitant with accumulation of an oxidative
stress marker, 4-hydroxynonenal, as an index of global lipid
peroxidation. In addition, CL hydroperoxides have been
identified as one of the major contributors to overall lipid
peroxidation and mitochondrial dysfunction early after injury
[41].
Growing interest has been focused on developing new
therapeutic strategies able to combat mitochondrial dys-
function. Several pharmacological agents are currently under
investigation, including novel antioxidants, uncoupling proteins
and mitochondrial permeability transition pore inhibitors
[30,42]. One of these agents, cyclosporine, a mitochondrial
permeability transition pore inhibitor, has shown benefits in
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Figure 2
Mitochondrial energy production. The mitochondrial electron transport chain is composed of five multimeric complexes. Electron transport between
complexes I to IV is coupled to extrusion of protons from complexes I, III and IV into the intermembrane space, creating an electrochemical gradient
(Δψ) across the inner mitochondrial membrane. Protons then flow through complex V (ATP synthase), which utilizes the energy to synthesize ATP
from ADP. Some common mitochondrial respiratory chain inhibitors are shown. C, cytochrome c; Q, ubiquinone.experimental traumatic brain injury models with improvement
of mitochondrial function, cerebral metabolism and tissue
damage [43,44]. The effect of cyclosporin on immune
function and outcome is currently under investigation in
clinical traumatic brain injury [45].
Oxidative stress
While small fluctuations in the steady-state concentrations of
some free radicals may actually play a role in intracellular
signaling in normal physiology [46], uncontrolled increases
in the generation of free radicals exceed the capacity of
antioxidant mechanisms to defend against them, resulting in
oxidative stress with damage to lipids, proteins and DNA.
Among the major biologically relevant free radical species in
cells and biofluids are a one-electron product of oxygen
reduction, the superoxide anion radical, and its dismutation
product, hydrogen peroxide (H2O2). The latter can be further
reduced to a highly potent oxidant, the hydroxyl radical;
alternatively, hydrogen peroxide can be activated by heme-
peroxidases to reactive (oxoferryl) intermediates, which are
also very potent oxidants [47]. Up to 1% of all oxygen
consumption is estimated to form superoxide [5]. In the
mitochondria, superoxide can be produced by respiratory
complexes and individual enzymes on the outer
mitochondrial membrane, on both sides of the inner
mitochondrial membrane and in the matrix [48]. The relative
contribution of each site to the overall superoxide production
is tissue and respiratory state dependent. Complex I in the
brain [49] and complex III in the heart and lung [48,50] seem
to be the primary sources of mitochondrial superoxide
production under normal conditions. The rate of superoxide
production increases with state 4 respiration (when the
electron transport chain slows down and becomes more
reduced) and in the presence of inhibitors [20]. When the
electron transport chain is dysregulated or disrupted,
particularly at the level of complexes I and/or III, the
production and release of superoxide radicals increase
(Figure 3) [51]. Outside of mitochondria, NADPH oxidases,
particularly in polymorphonuclear neutrophils, macrophages
and endothelial cells [52], xanthine oxidase [53] and
cytochrome P450-dependent oxygenases [54] are the major
sources of superoxide production.
A family of specialized enzymes, superoxide dismutases
(SODs), convert superoxide to hydrogen peroxide, a
relatively stable molecule [55]. Although the dismutation of
superoxide to hydrogen peroxide can occur spontaneously,
the role of SODs is to increase the rate of the reaction to
that of a diffusion-controlled process. In the cytosol and the
intermembrane space of mitochondria, superoxide is
eliminated by Cu,Zn-SOD, whereas in the matrix it is
eliminated by MnSOD [48]. Glutathione peroxidase in turn
reduces hydrogen peroxide to water and molecular oxygen by
using glutathione [56].
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Figure 3
Mitochondrial oxidative stress. In the mitochondria, superoxide can be produced by respiratory complexes. Complex I in the brain and complex III in
the heart and lung seem to be the primary sources of mitochondrial superoxide production. Superoxide is detoxified by manganese superoxide
dismutase (MnSOD) to hydrogen peroxide (H2O2) in the mitochondria. Glutathione peroxidases (GPxs) convert hydrogen peroxide to water. Nitric
oxide (NO) generated from (mitochondrial) nitric oxide synthase (mt)NOS can compete with MnSOD and form peroxynitrite (ONOO-). Peroxynitrite
in turn initiates thiol oxidation or nitrosylation and tyrosine nitration. C, cytochrome c; O2-, superoxide; Q, ubiquinone.Another important free radical species produced by cells is
NO, whose formation from arginine and oxygen is catalyzed
by a family of NO synthases (NOSs). Although its presence,
localization and physiological role are debated, a mito-
chondrial NOS isoform (mtNOS), possibly associated with
the mitochondrial inner membrane, has recently been
described [57,58]. NO can bind to heme groups of hemo-
proteins, including cytochrome oxidase. In the latter case, the
important consequence is inhibition of respiration [59].
Chemically, NO is relatively inert. Similarly, superoxide itself is
not particularly redox reactive. However, the toxic potential of
both small radical species may be enhanced by their
interaction, which leads to the production of a very potent
oxidant, peroxynitrite (ONOO-) [60]. NO and peroxynitrite
exert differential inhibitory effects on the mitochondrial
electron transport chain. Reactions of peroxynitrite with
respiratory complexes and cytochrome c lead to their
inactivation via free radical mechanisms, including thiol
oxidation or nitrosylation and tyrosine nitration [61].
Mitochondrial ROS production and oxidative
signaling in apoptosis
Mitochondrial ROS production is one of the very early events
preceding collapse of mitochondrial membrane potential,
release of pro-apoptotic factors, and activation of caspases
[8]. However, specific mechanisms of enhanced ROS
generation in mitochondria and their translation into apoptotic
signals are not well understood. Cytochrome c, the major
player in post-mitochondrial caspase activation, was found to
have yet another, earlier function during the mitochondrial
stage of apoptosis. This role includes its interactions with a
mitochondria-specific phospholipid, CL. The result of this
interaction is a high affinity cytochrome c-CL complex which
acts as a specific and potent oxidant. In the presence of
hydrogen peroxide, this complex functions as a CL-specific
oxygenase catalyzing the oxidation of CL, which occurs early
in apoptosis [62]. This has been established in a variety of
cell lines undergoing apoptosis induced by pro-oxidant and
non-oxidant pro-apoptotic agents in vitro. Our studies in
experimental traumatic brain injury and hemorrhagic shock
confirmed that this mechanism is also functional in vivo
[41,63]. We have shown that selective oxidation of CL takes
place during apoptosis while other, more abundant phospho-
lipids (such phosphatidylcholine and phosphatidylethanol-
amine) remain non-oxidized in spite of the fact that they
contain sufficient amounts of polyunsaturated fatty acid
residues susceptible to oxidation [41].
The regulation of cytochrome c-CL interactions and the
peroxidase function of the complex are not fully understood.
However, several important details concerning this function of
cytochrome c are beginning to emerge. For example, binding
to CL turns off cytochrome c’s function as an electron carrier
but turns on its peroxidase activity [64]. Notably, oxidized CL
(CLox) has a markedly lower affinity for cytochrome c and
abandons the complex [65,66]. CL oxidation products (CLox;
mostly cardiolipin hydroperoxides) accumulate in the
mitochondria, leading to the release of pro-apoptotic factors
into the cytosol (Figure 4). The specific mechanisms through
which peroxidized CL induces a permeability transition in
mitochondria and the subsequent release of pro-apoptotic
factors need further analysis; however, this important task of
CLox has been documented both in cells during apoptosis as
well as isolated mitochondria [67]. It is essential, therefore, to
understand the metabolic mechanisms involved in controlling
CLox content in mitochondria. Interestingly, CL hydroper-
oxides are endogenous substrates for phospholipid-hydro-
peroxide glutathione peroxidase (Gpx IV) [68], and transgenic
mice overexpressing this enzyme are protected against
oxidative stress-induced apoptosis [69].
Mitochondrial apoptosis as a target for drug
discovery
Because apoptosis contributes to disease processes in many
critical illnesses, such as sepsis, trauma and acute respiratory
distress syndrome [2-4], it is a clinically relevant mechanism
that may represent a potential therapeutic target [70].
Mitochondrial ROS have become a target for drug discovery
in recent years because their production is characteristic of
early stages of apoptosis. Among many antioxidant agents,
stable nitroxide radicals have attracted attention due to their
ability to combine radical scavenging action with recycling
capacities [71]. By accepting one electron, nitroxide radicals
are converted to their respective hydroxylamines. These
hydroxylamines act as effective ROS scavengers to produce
nitroxides, that is, they undergo recycling [72]. Furthermore,
nitroxide radicals possess SOD mimetic activity [73,74].
Although nitroxides (such as 4-hydroxy-2,2,6,6-tetramethyl
piperidine-1-oxyl (TEMPOL)) have been extensively
investigated as successful cytoprotectors in a number of
experimental models of oxidative stress [75-79], the required
high concentrations (millimolar) have limited in vivo applica-
tions of nitroxides [80].
Several recent studies indicate that targeting of nitroxides to
mitochondria enhances their anti-apoptotic activity [81-84].
Dessolin and colleagues [81] have reported that accumula-
tion of TEMPOL in mitochondria was substantially increased
by conjugating it with a Salen-Mn(III) complex of o-vanillin
(EUK-134), and the targeted nitroxide delayed apoptosis after
an exogenous oxidative insult. Dhanasekaran and colleagues
[82] have also demonstrated that a mitochondria-targeted
conjugate of nitroxide with a positively charged triphenyl-
phosphonium (mitocarboxy peroxyl) inhibited peroxide-induced
oxidative damage and apoptosis. We have previously reported
a significant increase in the cytoprotective effects of 4-amino
TEMPO (4-AT) by coupling it to a segment of a membrane-
active compound, gramicidin S [84]. Furthermore, the activity
of the mitochondrially targeted electron acceptor conjugates
of 4-AT with gramicidin S prolonged survival in rats subjected
to lethal hemorrhagic shock even in the absence of
resuscitation with asanguinous fluids or blood [63].
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in critical illness
During critical illness, a number of cell types in different
tissues undergo apoptosis [6,70]. Excessive cell death,
including apoptotic cell death, contributes to the patho-
genesis of traumatic brain injury and organ failure in sepsis
[2,4]. Paradoxically, insufficiency of cell death may also be
associated with the pathogenesis of critical illnesses. An
important example is delayed apoptosis and ineffective
clearance of neutrophils, which is associated with multiple
organ failure [85,86]. Neutrophil apoptosis and their effective
clearance are particularly important in modulation of the
inflammatory response [87]. Prolongation of neutrophil life
span may have important implications in delayed resolution of
inflammation. Therefore, timely elimination of excessive
neutrophils via apoptotic pathways is imperative. Neutrophils
are produced at a rate of 1 to 2 × 1011 cells per day and they
survive in the circulation for approximately 48 hours before
undergoing apoptosis [88]. Neutrophils can undergo apop-
tosis via intrinsic and extrinsic pathways, the latter requiring
mitochondrial amplification [89]. The role played by
mitochondria in the regulation of cell life span is perhaps
most crucial in neutrophils compared to other cell types in the
body [90]. Mature neutrophils contain few mitochondria,
although the amount of these apoptosis ‘orchestrating’
organelles is sufficient to trigger and execute common
pathways of apoptosis and to express the signals essential
for the effective clearance of them [89,91].
Macrophage recognition and uptake of apoptotic cells (also
termed ‘efferocytosis’) is an important cell-cell interaction
regulating inflammation [92,93]. This interaction triggers not
only effective clearance of apoptotic cells but also causes
suppression of the inflammatory response, thus limiting the
local tissue response and normally leading to quiet cell
removal [94-96]. In contrast, inefficient apoptotic cell
clearance is pro-inflammatory and immunogenic [97]. The
recognition of different types of apoptotic cells, including
neutrophils, by macrophages is largely dependent on the
appearance on the cell surface of an anionic phospholipid, PS,
which is normally confined to the cytosolic leaflet of the
plasma membrane [98]. Thus, externalization of PS during
apoptosis generates an ‘eat-me’ signal for macrophages
[94,99]. Development and utilization of non-toxic molecules
regulating apoptosis, and particularly phagocytosis of
neutrophils, may provide a novel therapeutic strategy. Notably,
asymmetric distribution of PS across the plasma membrane is
mainly due to the activity of a specialized enzymatic
mechanism, aminophospholipid translocase, APLT [98]. The
enzyme contains redox-sensitive thiol groups and its inhibition
by oxidative/nitrosative stress results in PS externalization
(Figure 5) [100]. This suggests that nitrosylation of sensitive
cysteine residues in APLT may be a promising strategy to
research in the drug discovery programs aimed at regulating
inflammatory responses. Indeed, our experiments with
neutrophil-like HL-60 cells demonstrated that S-nitrosylation of
critical cysteine residues in APLT using a cell-permeable trans-
nitrosylating agent, S-nitroso-acetyl-cysteine, resulted in
egression of PS, rendering these cells recognizable by
macrophages [100]. This approach represents a new strategy
in regulating the life-span of neutrophils and their clearance by
macrophages. Further development of the strategy for
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Figure 4
Mitochondrial reactive oxygen species production and oxidative signaling in apoptosis. Interactions of cytochrome c (Cyt c) with the mitochondria
specific phospholipid cardiolipin (CL) result in a high affinity cytochrome c-CL complex that acts as a specific and potent oxidant. In the presence
of hydrogen peroxide, this complex functions as a CL-specific oxygenase catalyzing oxidation of CL. Binding with CL turns off cytochrome c’s
function as an electron carrier but turns on its peroxidase activity. Oxidized CL has a markedly lower affinity for cytochrome c and abandons the
complex. CL oxidation products (CLox; mostly cardiolipin hydroperoxides) accumulate in the mitochondria, leading to the release of pro-apoptotic
factors into the cytosol (Figure 4). AIF, apoptosis inducing factor; ANT, adenine nucleotide translocase; VDAC, voltage-dependent anion-selective
channel.expedited clearance of neutrophils in vivo may be useful in
overcoming the consequences of insufficient and delayed
elimination of neutrophils causing dysregulation and
exacerbation of inflammatory responses. It is tempting to
speculate that the delivery of reagents required for trans-
nitrosylation of target cysteine residues in APLT may be
achieved using novel nanoparticle-based vectors [101]. Lately,
carbon nanotubes have demonstrated significant potential in
the targeted delivery of their cargoes to accomplish temporally
and spatially predetermined release of specific regulators and
inhibitors [102,103]. While these strategies may look
futuristic, recent exponential development of nanotechno-
logies promises that these plans are not overly optimistic.
Conclusion
In this review, we briefly considered several theoretical issues
relevant to the role that mitochondria play in oxidative stress,
oxidative signaling and the regulation of apoptosis. It is true that
translation of these theoretical considerations into practical
predictors of outcomes, biomarkers and new effective drugs in
critical illnesses may take some time. However, we are
encouraged by the previous experiences of many successful
researchers in the field of drug discovery who proved that
‘there is nothing more practical than a good theory’.
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